Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Atea Pharmaceuticals, Inc. Common Stock

AVIR

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Last trade $3.94
Day change -$0.18 (-4.37%)
Day range $3.90 – $4.14
Volume 202,086
Market cap $331M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$330.85M
Price / earnings
—
Price / book
1.88×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.36×

Profitability

Earnings per share
-$1.94
Return on assets
-77.43%
Return on equity
-88.46%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8×
Quick ratio
8×
Cash ratio
3.91×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$140.57M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AVIR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$6.92M$6.95M$6.87M$7.12M$7.22M$9.07M$9.46M$13.36M
Research and development$27.09M$28.15M$41.13M$47.82M$38.35M$32.28M$29.58M$25.67M
Total operating expenses$34.01M$35.1M$48.01M$54.93M$45.57M$41.35M$39.04M$39.03M
Operating income-$34.01M-$35.1M-$48.01M-$54.93M-$45.57M-$41.35M-$39.04M-$39.03M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$32.12M-$32.91M-$45.39M-$51.64M-$41.85M-$36.95M-$34.07M-$33.32M
Income taxes$38K$24K$50K-$6.77M$196K$207K$203K$225K
Net income-$32.16M-$32.93M-$45.44M-$44.87M-$42.05M-$37.16M-$34.27M-$33.54M
Net income attributable to common shareholders-$32.16M-$32.93M-$45.44M-$44.87M-$42.05M-$37.16M-$34.27M-$33.54M
EBITDA-$33.91M-$35M-$47.9M-$54.83M-$45.46M-$41.24M-$38.94M-$38.92M
Basic earnings per share-$0.40-$0.41-$0.57-$0.58-$0.53-$0.44-$0.40-$0.40
Diluted earnings per share-$0.40-$0.41-$0.57-$0.58-$0.53-$0.44-$0.40-$0.40

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026

Atea Pharmaceuticals announced Phase 1 results demonstrating that its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus treatment has a low risk of drug-drug interactions with commonly used medications like omeprazole and rosuvastatin. The company also presented preclinical data showing AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus, exhibits high antiviral potency and in vivo efficacy, with plans to initiate first-in-human studies mid-2026.

GlobeNewswire Inc.

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Atea Pharmaceuticals announced preclinical results showing AT-587 and AT-2490 are potent inhibitors of Hepatitis E Virus (HEV), demonstrating 30-150 fold greater potency compared to sofosbuvir and ribavirin. The company plans to initiate Phase 1 clinical trials for AT-587 mid-2026, addressing an unmet medical need as no antivirals are currently approved for HEV treatment.

GlobeNewswire Inc.

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 14, 20181-for-11reverse split